Anti-angiogenic function is via inhibition of VEGFR-2-PDGFR- and Raf-kinase properties [5–7], signaling pathways identified as a close rationale in HCC study and providing survival benefits in advanced HCC [Barcelona Clinic Liver Cancer (BCLC) stage C] [7–12]. This evidence concerns the gene KDR and hepatocellular carcinoma.